Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal diseases. Since its acquisition by Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals) in 2015, Salix has operated as a significant gastroenterology (GI) business unit. The company develops and markets a portfolio of innovative products aimed at treating conditions such as irritable bowel syndrome with diarrhea (IBS-D), hepatic encephalopathy (HE), opioid-induced constipation (OIC), and traveler's diarrhea. Salix's mission is to improve patients' lives by providing healthcare professionals with effective GI solutions, driven by research and a deep understanding of digestive health.
Serves as the central hub for Salix's strategic, operational, and commercial activities within the Bausch Health framework, overseeing its gastroenterology product portfolio, R&D direction, and market strategies.
Located in a modern corporate office park, facilitating collaboration and innovation. The campus offers state-of-the-art amenities typical of a leading pharmaceutical company headquarters.
As part of Bausch Health, the work culture is likely focused on performance, innovation in healthcare, and a commitment to patient well-being. Emphasis is placed on scientific rigor and commercial execution in the pharmaceutical sector.
The Bridgewater headquarters is crucial for integrating Salix's specialized GI expertise with Bausch Health's broader resources, enabling effective management and growth of its product lines like XIFAXAN®, TRULANCE®, and RELISTOR®.
While Salix Pharmaceuticals primarily focuses on the U.S. market for its gastroenterology products, its innovations and treatments reach patients globally through the extensive international infrastructure and distribution network of its parent company, Bausch Health. Bausch Health supports commercial operations, regulatory affairs, and market access in numerous countries worldwide, allowing Salix's GI therapies to benefit a broader patient population.
400 Somerset Corporate Blvd
Bridgewater
New Jersey
USA
Address: 8510 Colonnade Center Dr, Raleigh, NC 27615, USA (Bausch Health Office)
Acts as a significant operational and R&D site, capitalizing on the region's strong pharmaceutical and biotech ecosystem and historical ties to Salix's legacy operations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, SALIX DATA' leadership includes:
SALIX DATA has been backed by several prominent investors over the years, including:
Bausch Health has experienced key leadership appointments in the past year impacting segments that include Salix Pharmaceuticals. Notable changes include a new head for the Diversified Products segment.
Discover the tools SALIX DATA uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
As Salix Pharmaceuticals is a division of Bausch Health, employees typically use the @bauschhealth.com email domain. Common corporate email formats include [first].[last]@bauschhealth.com and [first_initial][last]@bauschhealth.com.
[first].[last]@bauschhealth.com or [first_initial][last]@bauschhealth.com
Format
john.smith@bauschhealth.com or jsmith@bauschhealth.com
Example
80%
Success rate
Bausch Health Press Releases • May 7, 2024
Bausch Health announced its Q1 2024 financial results, reporting consolidated revenues of $2.15 billion. The Salix segment reported revenues of $512 million, a 6% increase compared to Q1 2023, primarily driven by growth in XIFAXAN®....more
Bausch Health Press Releases • February 22, 2024
Bausch Health released its Q4 and full-year 2023 financial results. For the full year, the Salix segment reported revenues of $2.088 billion, demonstrating continued performance of its key gastroenterology products....more
Salix Pharmaceuticals News • October 23, 2023
Salix Pharmaceuticals announced it would be presenting nine scientific posters, including new data on XIFAXAN® (rifaximin), at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting. This underscores their commitment to advancing GI care....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including SALIX DATA, are just a search away.